carmustine has been researched along with Multiple Myeloma in 202 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative." | 9.16 | Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. ( Arai, S; Chen, AI; Johnston, LJ; Laport, GG; Lowsky, R; McMillan, A; Miklos, DB; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Weng, WK, 2012) |
| "This Eastern Cooperative Oncology Group trial evaluated 268 previously untreated patients with active multiple myeloma randomized to vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or VBMCP plus HiCy and recombinant IFN." | 9.14 | The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology ( Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF, 2009) |
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 9.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Carmustine (BCNU) is known to have modest activity in multiple myeloma; however, resistance to BCNU manifests by the activity of O6-methylguanine methyltransferase (MGMT)." | 9.12 | O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. ( Bahlis, N; Batts, ED; Fu, P; Gerson, SL; Kane, D; Liu, L; Maisel, C; O'Brien, T; Remick, S, 2007) |
| "Eighty-nine previously untreated patients with multiple myeloma and prognostic factors indicating a good prognosis were randomized to either oral melphalan plus prednisone (MP) in combination with recombinant interferon-alpha (rIFN-alpha) or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with rIFN-alpha." | 9.09 | Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud ( Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K, 2001) |
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 9.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone." | 9.08 | VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). ( Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M, 1998) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 9.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM)." | 9.07 | Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. ( Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A, 1993) |
| "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM)." | 9.07 | Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. ( Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M, 1991) |
| "From October 1983 until December 1986, 164 patients with multiple myeloma stage II-III were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) with multidrug chemotherapy (MDC)." | 9.06 | Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1990) |
| "86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44)." | 9.06 | Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A, 1989) |
| "A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)." | 9.06 | Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 9.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 9.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus prednisone (CBP) (42 patients)." | 9.04 | Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. ( Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR, 1979) |
| "We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen." | 7.71 | Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. ( Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G, 2001) |
| "A total of 65 patients (35 male/30 female) with multiple myeloma primarily (33) or secondarily (32) resistant to melphalan and prednisone were treated with vincristine, carmustine (BCNU), doxorubicin, and high-dose dexamethasone (VBAD) at 4-week intervals." | 7.68 | Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). ( Alcalá, A; Bladé, J; Fontanillas, M; García-Conde, J; Hernández, JM; Martínez, M; Moro, J; Ortega, F; San Miguel, J; Sanz-Sanz, MA, 1992) |
| "Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma." | 7.67 | [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. ( Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD, 1984) |
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 7.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Melphalan, ifosfamide, prednisolone, nitrosourea [1-(4-amino-2-methyl-5-pyrimidyl)-3-(2-chloroethyl)-3-nitrosourea hydrochloride, ACNU or 1, 3-bis (2-chloroethyl)-1-nitrosourea, BCNU] and vincristine (MIP-NV) were given in combination to 48 patients with multiple myeloma." | 7.67 | Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine. ( Ishii, H, 1988) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 7.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period." | 7.67 | Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). ( Bladé, J; Cervantes, F; Feliu, E; Grañena, A; Marín, P; Montserrat, E; Nomdedeu, B; Rozman, C, 1986) |
| "A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine." | 7.67 | Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. ( Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD, 1985) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 7.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "A 53-year-old man with multiple myeloma and plasma cell luekemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone." | 7.66 | Optic neuroretinitis in association with BCNU and procarbazine therapy. ( Lennan, RM; Taylor, HR, 1978) |
| "Fourteen patients with multiple myeloma resistant to melphalan plus prednisone were treated with BCNU 50 mg/m2 plus cyclophosphamide 200 mg/m2 on day 1, adriamycin 20 mg/m2 on day 2 and prednisone 60 mg orally, daily for days 1 through 5." | 7.66 | Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma. ( Klahr, C; Presant, CA, 1978) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | 6.68 | A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | 6.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | 6.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group. ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "Thrombocytopenia was the most frequent form of toxicity." | 6.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "A total of 123 patients with lymphoma receiving the BEAM (carmustine, etoposide, aracytin, and melphalan) conditioning regimen had a significant 5% drop in mean forced vital capacity and total lung capacity but no significant change in forced expiratory volume in one second/forced vital capacity ratio nor in diffusion lung capacity of carbon monoxide adjusted to volume." | 5.34 | Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience. ( Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A, 2020) |
| "High-dose melphalan has been the standard conditioning regimen for auto-SCT in multiple myeloma (MM) for decades." | 5.19 | A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma. ( Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N, 2014) |
| "Single autologous hematopoietic cell transplant (AHCT) with high-dose melphalan prolongs survival in patients with multiple myeloma but is not curative." | 5.16 | Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. ( Arai, S; Chen, AI; Johnston, LJ; Laport, GG; Lowsky, R; McMillan, A; Miklos, DB; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Weng, WK, 2012) |
| "This Eastern Cooperative Oncology Group trial evaluated 268 previously untreated patients with active multiple myeloma randomized to vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) or VBMCP plus HiCy and recombinant IFN." | 5.14 | The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology ( Friedenberg, WR; Greipp, PR; Jacobus, S; Kyle, RA; Rajkumar, SV; Slabber, CF, 2009) |
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 5.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Carmustine (BCNU) is known to have modest activity in multiple myeloma; however, resistance to BCNU manifests by the activity of O6-methylguanine methyltransferase (MGMT)." | 5.12 | O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. ( Bahlis, N; Batts, ED; Fu, P; Gerson, SL; Kane, D; Liu, L; Maisel, C; O'Brien, T; Remick, S, 2007) |
| " We hypothesized that patients with the less stable variant have a decreased ability to detoxify chemotherapeutic substrates, including melphalan, and have an altered outcome following treatment for multiple myeloma." | 5.10 | Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. ( Adamson, PJ; Allan, JM; Ashcroft, AJ; Child, JA; Dasgupta, RK; Davies, FE; Dring, AM; Fenton, JA; Morgan, GJ; Roddam, PL; Rollinson, S, 2003) |
| "Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years." | 5.09 | The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "Eighty-nine previously untreated patients with multiple myeloma and prognostic factors indicating a good prognosis were randomized to either oral melphalan plus prednisone (MP) in combination with recombinant interferon-alpha (rIFN-alpha) or combination chemotherapy with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with rIFN-alpha." | 5.09 | Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud ( Anagnostopoulos, N; Barbarousi, D; Bourantas, K; Dimopoulos, MA; Gregoraki, B; Maniatis, A; Pouli, A; Tzilianos, M; Venetis, E; Vyniou, N; Zervas, K, 2001) |
| "Melphalan and prednisone (MP) has been the standard treatment for multiple myeloma (MM) for the last 30 years." | 5.09 | Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. ( Alcalá, A; Besalduch, J; Besses, C; Bladé, J; Brunet, S; Carbonell, F; Carnero, M; Conde, E; Escudero, ML; Estapé, J; Esteve, J; Fernández-Calvo, J; Font, L; Fontanillas, M; García-Conde, J; Gardella, S; Hernández-Martín, J; Maldonado, J; Martí, JM; Montserrat, E; Moro, MJ; Ortega, F; Ribera, JM; Rozman, C; San Miguel, JF; Trujillo, J, 2001) |
| " From January 1985 to December 1989, 487 patients with multiple myeloma (MM) were randomized to receive melphalan and prednisone (MP) versus alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, BCNU, adriamycin, and prednisone (VBAP)." | 5.08 | Treatment of multiple myeloma in elderly people: long-term results in 178 patients. ( Alcalá, A; Besses, C; Bladé, J; Estapé, J; Fontanillas, M; García-Conde, J; Maldonado, J; Montserrat, E; Moro, MJ; Muñoz, M; Rozman, C; San Miguel, J, 1996) |
| "The Eastern Cooperative Oncology Group (ECOG) performed a Phase III comparison of melphalan and prednisone (MP) with vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone (VBMCP) in an attempt to determine which of these regimens should be the standard treatment for multiple myeloma." | 5.08 | Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. ( Abramson, N; Glick, JH; Harrington, DP; Knospe, W; Kyle, RA; Oken, MM, 1997) |
| "263 patients (median age 65+/-10 years) with multiple myeloma were treated with cyclophosphamide-prednisone." | 5.08 | VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). ( Azais, I; Bernard, JF; De Gramont, A; Doyen, C; Euller-Ziegler, L; Grosbois, B; Laporte, JP; Le Loët, X; Ménard, JF; Michaux, JL; Mineur, P; Monconduit, M; Peny, AM; Pollet, JP; Wetterwald, M, 1998) |
| "We investigated the feasibility of escalating doses of dacarbazine (DTIC) in combination with high-dose cyclophosphamide, carmustine, and etoposide (CBV) given with autologous stem-cell transplantation in 33 patients with relapsed or refractory lymphoma or multiple myeloma." | 5.07 | Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. ( Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L, 1994) |
| "This prospective study was undertaken to evaluate the efficacy of combination chemotherapy with alternating cycles of vincristine, doxorubicin, and dexamethasone (VAD) and prednisone, vindesine, carmustine, and cyclophosphamide (PECC) in poor-risk multiple myeloma (MM)." | 5.07 | VAD-PECC regimen in the treatment of advanced-stage multiple myeloma. ( Benboubker, L; Colombat, P; Combe, M; Delain, M; Goupille, P; Lamagnère, JP; Linassier, C; Luthier, F; Petitdidier, C; Reisenleiter, M, 1994) |
| "To determine whether combination chemotherapy with alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, carmustine (BCNU), Adriamycin (doxorubicin; Farmitalia, Carlo-Erba Laboratories, Spain), and prednisone (VBAP) is better than the standard melphalan-prednisone (MP) regimen in multiple myeloma (MM)." | 5.07 | Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. ( Alcalá, A; Alonso, C; Besalduch, J; Bladé, J; García-Conde, J; Maldonado, J; Moro, MJ; San Miguel, JF; Sanz, MA; Zubizarreta, A, 1993) |
| "From September 1975 to December 1986, 115 consecutive previously untreated patients with multiple myeloma (MM) were treated with combination chemotherapy consisting of BCNU, cyclophosphamide, melphalan, vincristine, and prednisone (M-2)." | 5.07 | Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. ( Baggio, G; Bolzonella, S; Casara, D; Chiarion-Sileni, V; De Besi, P; Favaretto, A; Frizzarin, M; Paccagnella, A; Salvagno, L; Soesan, M, 1991) |
| "The efficacy of alternating vincristine, melphalan (M), cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin, and prednisone (VMCP/VBAP) polychemotherapy was compared with the M and prednisone (MP) regimen as induction treatment in multiple myeloma (MM)." | 5.07 | Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. ( Andriani, A; Avvisati, G; Barbui, T; Boccadoro, M; Cantonetti, M; Carotenuto, M; Comotti, B; Dammacco, F; Marmont, F; Tribalto, M, 1991) |
| "From October 1983 until December 1986, 164 patients with multiple myeloma stage II-III were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) with multidrug chemotherapy (MDC)." | 5.06 | Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden. ( Hellquist, L; Hjorth, M; Holmberg, E; Magnusson, B; Rödjer, S; Westin, J, 1990) |
| "86 previously untreated patients with multiple myeloma stage III entered a randomized trial comparing combination chemotherapy (VMCP/VBAP) (n = 42) with intermittent oral melphalan and prednisone (MP) treatment (n = 44)." | 5.06 | Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS. ( Ahre, A; Björeman, M; Björkholm, M; Brenning, G; Gahrton, G; Gyllenhammar, H; Järnmark, M; Johansson, B; Juliusson, G; Osterborg, A, 1989) |
| "A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU)." | 5.06 | Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience. ( Brunner, K; Coleman, M; Cooper, MR; Cornwell, GG; Glowienka, LP; Henderson, E; Kochwa, S; McIntyre, OR; Pajak, TF; Rafla, S, 1988) |
| "Four hundred forty previously untreated patients with active multiple myeloma were entered into a randomized trial (Southwest Oncology Group [SWOG] study 7927/28) comparing vincristine, melphalan, Cytoxan (Mead Johnson & Company, Evansville, Ind), and prednisone (VMCP) alternating with vincristine, BCNU, Adriamycin (Adria Laboratories, Columbus, Ohio) and prednisone (VBAP) with or without levamisole with vincristine, Cytoxan, and prednisone (VCP) with or without levamisole for induction therapy." | 5.06 | Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. ( Bonnet, J; Carter, S; Costanzi, JJ; Dabich, L; Dixon, DO; Durie, BG; Files, JC; Rivkin, S; Salmon, SE; Stephens, R, 1986) |
| "67 previously untreated patients with multiple myeloma were entered on a randomized clinical trial to determine whether the use of combination chemotherapy including vincristine, carmustine, alkylating agents, and prednisone was more effective than conventional therapy with melphalan and prednisone." | 5.06 | Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy. ( Bjark, P; Bondevik, A; Bull, O; Dehli, O; Kildahl-Andersen, O; Kvambe, V; Lamvik, J; Nordahl, E; Ytrehus, K, 1986) |
| "Thirty-five previously untreated patients with multiple myeloma were treated with a 60-week course of alternating, potentially non-cross-resistant chemotherapy combinations (melphalan and prednisone; vincristine, cyclophosphamide, doxorubicin, and prednisone; and carmustine, melphalan, and prednisone), alternating every 15 weeks in an attempt to prevent the development of drug resistance." | 5.05 | Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness. ( Bunn, PA; Carney, DN; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Morstyn, G; Schechter, GP, 1984) |
| " To evaluate possible synergism in the treatment of human multiple myeloma (MM), 23 evaluable patients who had relapsed with standard treatment were treated with cisplatin, BCNU, CTX, and prednisone." | 5.05 | Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. ( Broun, GO; Cohen, HJ; Hiramoto, RN; Petruska, PJ, 1982) |
| "A prospective randomized trial in patients with previously untreated multiple myeloma was performed comparing carmustine (BCNU), cyclophosphamide, and prednisone (BCP) to melphalan (Alkeran) and prednisone (AP)." | 5.05 | Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma. ( Abramson, N; Bennett, JM; Horton, J; Lurie, P; Mietlowski, WL; Schilling, A, 1982) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 5.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Thirty-two evaluable good risk patients with multiple myeloma received a 70-day tapering course of prednisone beginning at a dose of 1." | 5.05 | Response rate and survival in myeloma patients receiving prednisone alone. ( Cornwell, GG; Kyle, RA; Leone, L; McIntyre, OR; Pajak, TF, 1985) |
| "Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) against a regimen employing oral melphalan (MP)." | 5.04 | Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. ( Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF, 1979) |
| "Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus prednisone (CBP) (42 patients)." | 5.04 | Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU. ( Blom, J; Gailani, S; Holland, JF; Kyle, RA; McIntyre, OR; Pajak, TF; Seligman, BR, 1979) |
| "A number of cooperative-group and single-institution studies have shown that BCNU used in combination with prednisone alone or with melphalan,cyclophosphamide, and prednisone is useful for remission induction in patients with previously untreated multiple myeloma." | 5.04 | Nitrosoureas in multiple myeloma. ( Salmon, SE, 1976) |
| "The effects of various regimens of melphalan combination chemotherapy were evaluated in 508 patients with multiple myeloma." | 5.04 | Remission maintenance therapy for multiple myeloma. ( , 1975) |
| "Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone." | 5.04 | Combination therapy for myelomatosis. ( Azam, L; Delamore, IW, 1974) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| "The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres." | 3.75 | The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vorkurka, S, 2009) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen." | 3.71 | Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. ( Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G, 2001) |
| "In 19 patients with recently diagnosed multiple myeloma 3-week cycles of vincristine, BCNU, melphalan, cyclophosphamide and prednisone alternating with interferon were administered over 6-12 months." | 3.68 | [Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B]. ( Gola, A; Kotlarek-Haus, S; Urbaniak-Kujda, D; Usnarska-Zubkiewicz, L; Wołowiec, D, 1993) |
| "A total of 65 patients (35 male/30 female) with multiple myeloma primarily (33) or secondarily (32) resistant to melphalan and prednisone were treated with vincristine, carmustine (BCNU), doxorubicin, and high-dose dexamethasone (VBAD) at 4-week intervals." | 3.68 | Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD). ( Alcalá, A; Bladé, J; Fontanillas, M; García-Conde, J; Hernández, JM; Martínez, M; Moro, J; Ortega, F; San Miguel, J; Sanz-Sanz, MA, 1992) |
| "Seventy patients with progressive multiple myeloma received combination chemotherapy with cyclophosphamide and prednisolone (CP), BCNU, cyclophosphamide, procarbazine and prednisolone (BCPP), and MCNU, cyclophosphamide, melphalan and prednisolone (MCMP) as first line treatment." | 3.68 | [Combination chemotherapy of multiple myeloma]. ( Ito, T; Saito, Y; Uzuka, Y, 1990) |
| "Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma." | 3.67 | [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. ( Busch, FW; Ostendorf, P; Stapelfeld, S; Steinke, B; Waller, HD, 1984) |
| "37 consecutive, previously untreated patients with advanced multiple myeloma (16 patients Stage II, 21 patients Stage III) were treated with a five drug regimen consisting of carmustine, melphalan, vincristine, cyclophosphamide and prednisolone (M-2-protocol) in a prospective manner." | 3.67 | Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma. ( Bauer, K; Bettelheim, P; Gössinger, H; Hinterberger, W; Korninger, K; Lechner, K; Neumann, E; Niessner, H; Pabinger-Fasching, I, 1984) |
| "Fourteen patients with stage III aggressive multiple myeloma were treated by high dose chemotherapy (carmustine, etoposide and melphalan) and total body irradiation." | 3.67 | Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft. ( Benbunan, M; Brouet, JC; Castaigne, S; Cosset, JM; Fermand, JP; Gerota, J; Lévy, Y; Seligmann, M, 1989) |
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 3.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Melphalan, ifosfamide, prednisolone, nitrosourea [1-(4-amino-2-methyl-5-pyrimidyl)-3-(2-chloroethyl)-3-nitrosourea hydrochloride, ACNU or 1, 3-bis (2-chloroethyl)-1-nitrosourea, BCNU] and vincristine (MIP-NV) were given in combination to 48 patients with multiple myeloma." | 3.67 | Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine. ( Ishii, H, 1988) |
| "33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)." | 3.67 | M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988) |
| "In a phase II study 28 patients with advanced multiple myeloma were treated with a five drug regimen consisting of vincristine, BCNU, adriamycin, melphalan and dexamethasone." | 3.67 | VBAMDex chemotherapy in advanced multiple myeloma. ( Deicher, H; Glück, S; Peest, D; Schedel, I; Schmoll, HJ; Schumacher, K, 1988) |
| "99 patients with multiple myeloma were treated over a period of 6 1/2 years; 62 of these were initially treated with vincristine, carmustine, cyclophosphamide, melphalan and prednisone: M 2-Protocol." | 3.67 | [Results with the use of the M-2 protocol in plasmacytoma]. ( Ho, AD; Hunstein, W; Keilholz, U; Theml, H; Wittkamp, S, 1986) |
| "A total of 33 evaluable patients with multiple myeloma refractory to alkylating agents were treated with the regimen vincristine, BCNU, doxorubicin, and prednisone (VBAP) at 3-week intervals in a single institution for a 5-yr period." | 3.67 | Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). ( Bladé, J; Cervantes, F; Feliu, E; Grañena, A; Marín, P; Montserrat, E; Nomdedeu, B; Rozman, C, 1986) |
| "A group of 46 patients with melphalan-resistant multiple myeloma was treated according to the M-2 protocol with melphalan, prednisolone, BCNU, cyclophosphamide, and vincristine." | 3.67 | Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. ( Becherer, C; Busch, FW; Ostendorf, P; Steinke, B; Waller, HD, 1985) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 3.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "In order to study the response of patients with multiple myeloma of the bones (MM) to various anti-cancer drugs (Melphalan M, Cyclophosphamide Cy, Nitrosourea NU, Vincristine V, Adriamycine A and Prednisone P), 70 MM received the following treatment : 1) Induction therapy : a) M and P or b) M and Cy and P ; 2) Levelling with partial or complete response : V Cy P (in case a) or V M Cy P (in case b) ; 3) Relapse : A and NU." | 3.66 | [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years]. ( Bataille, R; Blotman, F; Bussière, JL; Ciurana, AJ; Lopitaux, R; Morlock, G; Rampon, S; Rosenberg, F; Sany, J; Serre, H; Simon, L, 1980) |
| "A 53-year-old man with multiple myeloma and plasma cell luekemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone." | 3.66 | Optic neuroretinitis in association with BCNU and procarbazine therapy. ( Lennan, RM; Taylor, HR, 1978) |
| "Fourteen patients with multiple myeloma resistant to melphalan plus prednisone were treated with BCNU 50 mg/m2 plus cyclophosphamide 200 mg/m2 on day 1, adriamycin 20 mg/m2 on day 2 and prednisone 60 mg orally, daily for days 1 through 5." | 3.66 | Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma. ( Klahr, C; Presant, CA, 1978) |
| "LDL cholesterol was lower in the 131 multiple myeloma patients than in healthy controls and the fractional clearance rate (FCR, in units per minute) in the 14 multiple myeloma patients was twice that in 14 paired healthy control subjects." | 2.71 | Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. ( Bydlowski, SP; Chiattone, CS; Hungria, VT; Latrilha, MC; Maranhão, RC; Rodrigues, DG, 2004) |
| "Severe infections were seen as often with VBMCP as with VBMCP + rIFN(alpha2) (13% vs." | 2.69 | The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. ( Greipp, PR; Kay, NE; Keimowitz, RM; Kyle, RA; Lenhard, RE; Leong, T; Oken, MM; Van Ness, B, 1999) |
| "406 untreated multiple myeloma patients of stage I (n = 54), II (n = 148) and III (n = 204) were enrolled in the trial." | 2.68 | A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fett, W; Fischer, JT; Göbel, B; Leo, R; Peest, D, 1995) |
| "Patients had a diagnosis of multiple myeloma and had not previously been treated for this disease." | 2.68 | Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. ( Crowley, J; Modiano, MR; Salmon, SE; Villar-Werstler, P, 1996) |
| "Fifty-eight patients with previously untreated multiple myeloma were entered." | 2.68 | Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma. ( Gregory, SA; Greipp, PR; Kay, NE; Kyle, RA; O'Connell M, J; Oken, MM; Spiegel R, J; Tsiatis, A, 1996) |
| "In all cases, the ras mutation of the disease progression sample was identical to that found at diagnosis." | 2.68 | Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. ( Billadeau, D; Greipp, P; Kay, NE; Kyle, RA; Leong, T; Liu, P; Oken, MM; Quam, L; Van Ness, B, 1996) |
| "Standard therapy for multiple myeloma consists of cytotoxic chemotherapy plus glucocorticoids." | 2.67 | Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. ( Barlogie, B; Crowley, JJ; Finley, P; Grogan, TM; Pugh, RP; Salmon, SE, 1994) |
| "In the Vth MRC myelomatosis trial, the survival of 314 patients randomised to receive ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan) as first-line treatment was significantly longer than that of 316 patients given intermittent melphalan (M7) (p = 0." | 2.67 | Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. ( Chapman, C; Dunn, J; Kelly, K; MacLennan, IC, 1992) |
| "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study." | 2.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen ( Bartels, H; Bartl, R; Braun, HJ; Coldewey, R; Deicher, H; Fischer, JT; Gramatzki, M; Leo, R; Peest, D; von Broen, IM, 1990) |
| "136 untreated multiple myeloma patients of stage II and III were collected in the study." | 2.67 | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group. ( Cammerer, U; Coldewey, R; Deicher, H; Hein, R; Hoffmann, L; Konyar, H; Kreuser, ED; Peest, D; Selbach, J; von Broen, IM, 1990) |
| "Thrombocytopenia was the most frequent form of toxicity." | 2.65 | Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. ( Alexanian, R; Amare, M; Bonnet, J; Bottomley, R; Dixon, D; Haut, A; Salmon, S, 1982) |
| "Acute leukemia has developed in 14 patients." | 2.65 | The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. ( Bailey, AJ; Bergsagel, DE; Langley, GR; MacDonald, RN; Miller, AB; White, DF, 1979) |
| "Rapidly progressing relapsed/refractory multiple myeloma (RRMM) patients with compromised marrow have limited treatment options." | 1.91 | Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. ( Chari, A; Cho, HJ; Jakubowski, R; Moshier, E; Mouhieddine, TH; Parekh, S; Puliafito, B; Rattu, M; Richard, S; Richter, J; Rodriguez, C; Rossi, A; Sanchez, L; Steinberg, A; Thibaud, S, 2023) |
| "Extramedullary disease (EMD) in multiple myeloma (MM) is characterised by an aggressive biology and an adverse prognosis especially when occurring at relapse." | 1.40 | The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma. ( Buck, A; Duell, J; Einsele, H; Knop, S; Maeder, U; Rasche, L; Rosenwald, A; Strifler, S, 2014) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation." | 1.35 | Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. ( Bacon, P; Blijlevens, N; D'Addio, A; Einsele, H; Maertens, J; McCann, S; Niederwieser, D; Quinn, B; Rabitsch, W; Roosaar, A; Ruutu, T; Schouten, H; Schwenkglenks, M; Stone, R; Vokurka, S, 2008) |
| "We studied 19 breast cancer (BC) patients and 17 multiple myeloma (MM) patients entered in a high-dose chemotherapy (HDC) program of tandem autografting with CD34+ cell-selected PBPC." | 1.32 | Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation. ( Amodeo, R; Anghel, G; De Rosa, L; Majolino, I; Pandolfi, A; Riccardi, M, 2004) |
| "Bone resorption was assessed by urinary free pyridinoline (fPyr) and deoxypyridinoline (fDPyr), expressed as a ratio of the urinary creatinine concentration." | 1.31 | Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. ( Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE, 2000) |
| "One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved." | 1.30 | Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. ( Chen, MG; Gastineau, DA; Gertz, MA; Greipp, PR; Inwards, DJ; Kyle, RA; Lacy, MQ; Litzow, MR; Lust, JA; Pineda, AA; Tefferi, A; Witzig, TE, 1999) |
| " The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting." | 1.30 | Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. ( Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999) |
| "We report two patients who developed visual hallucinations during treatment with vincristine." | 1.29 | Visual hallucinations following treatment with vincristine. ( Chapman, CS; Ghosh, K; Murphy, P; Sivakumaran, M; Wood, JK, 1994) |
| "A case of non-secretory multiple myeloma presenting as primary plasma cell leukaemia in a 65 year old woman is presented." | 1.28 | Non-secretory multiple myeloma presenting as primary plasma cell leukaemia. ( Hernando, JC; Pais, JR; Pascual, J; Pérez Vaquero, MA; Sureda, A, 1992) |
| "Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support." | 1.28 | High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. ( Alexanian, R; Barlogie, B; Dicke, KA; Hester, JP; Horwitz, LH; LeMaistre, CF; Spinolo, JA; Ventura, GJ; Wallerstein, RO; Yau, JC, 1990) |
| "Multiple myeloma was diagnosed in a 65-year-old woman in 1974 who thereafter received five-drug M2 chemotherapy." | 1.28 | Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy. ( Factor, SM; Reed, LJ; van Hoeven, KH, 1990) |
| "Seven patients with metastatic tumors resistant to therapy with adriamycin, BCNU, plus cyclophosphamide received the same chemotherapy combined with amphotericin B." | 1.26 | Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia. ( Klahr, C; Presant, CA; Santala, R, 1977) |
| "Patients with asymptomatic or smoldering multiple myeloma should not be treated but should be observed closely for progression." | 1.26 | Management and prognosis of multiple myeloma. ( Elveback, LR; Kyle, RA, 1976) |
| "Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino-terminal, variant half (VL) or to the carboxyl-terminal, constant half (CL) of the Bence Jones protein." | 1.25 | Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy. ( Capra, JD; McLaughlin, CL; Solomon, A, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (44.55) | 18.7374 |
| 1990's | 61 (30.20) | 18.2507 |
| 2000's | 40 (19.80) | 29.6817 |
| 2010's | 9 (4.46) | 24.3611 |
| 2020's | 2 (0.99) | 2.80 |
| Authors | Studies |
|---|---|
| Mouhieddine, TH | 1 |
| Moshier, E | 1 |
| Thibaud, S | 1 |
| Puliafito, B | 1 |
| Rattu, M | 1 |
| Jakubowski, R | 1 |
| Sanchez, L | 1 |
| Rossi, A | 1 |
| Rodriguez, C | 1 |
| Richard, S | 1 |
| Cho, HJ | 1 |
| Parekh, S | 1 |
| Chari, A | 1 |
| Steinberg, A | 1 |
| Richter, J | 1 |
| Bou Akl, I | 1 |
| Matar, M | 1 |
| Khalil, PB | 1 |
| Massoud, R | 1 |
| Ghaoui, N | 1 |
| Karout, L | 1 |
| Zahreddine, A | 1 |
| Bazarbachi, A | 1 |
| El-Cheikh, J | 1 |
| Sivaraj, D | 1 |
| Bacon, W | 1 |
| Long, GD | 1 |
| Rizzieri, DA | 1 |
| Horwitz, ME | 1 |
| Sullivan, KM | 1 |
| Kang, Y | 1 |
| Li, Z | 1 |
| Chao, NJ | 1 |
| Gasparetto, C | 1 |
| Kalitin, NN | 1 |
| Buravtsova, IV | 1 |
| Rasche, L | 1 |
| Strifler, S | 1 |
| Duell, J | 1 |
| Rosenwald, A | 1 |
| Buck, A | 1 |
| Maeder, U | 1 |
| Einsele, H | 3 |
| Knop, S | 1 |
| Wang, TF | 1 |
| Fiala, MA | 1 |
| Cashen, AF | 1 |
| Uy, GL | 1 |
| Abboud, CN | 1 |
| Fletcher, T | 1 |
| Wu, N | 1 |
| Westervelt, P | 1 |
| DiPersio, JF | 1 |
| Stockerl-Goldstein, KE | 1 |
| Vij, R | 1 |
| Cioch, M | 1 |
| Jawniak, D | 1 |
| Kotwica, K | 1 |
| Wach, M | 1 |
| Mańko, J | 1 |
| Gorący, A | 1 |
| Klimek, P | 1 |
| Mazurkiewicz, E | 1 |
| Jarosz, P | 1 |
| Hus, M | 1 |
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
| Veeraputhiran, M | 1 |
| Jain, T | 1 |
| Deol, A | 1 |
| Ayash, L | 1 |
| Kim, S | 1 |
| Dyson, G | 1 |
| Bhutani, D | 1 |
| Lum, LG | 1 |
| Ratanatharathorn, V | 2 |
| Uberti, JP | 1 |
| Abidi, MH | 1 |
| Paiva, B | 1 |
| Vidriales, MB | 1 |
| Cerveró, J | 1 |
| Mateo, G | 1 |
| Pérez, JJ | 1 |
| Montalbán, MA | 1 |
| Sureda, A | 4 |
| Montejano, L | 1 |
| Gutiérrez, NC | 1 |
| García de Coca, A | 1 |
| de Las Heras, N | 1 |
| Mateos, MV | 2 |
| López-Berges, MC | 1 |
| García-Boyero, R | 1 |
| Galende, J | 1 |
| Hernández, J | 1 |
| Palomera, L | 2 |
| Carrera, D | 2 |
| Martínez, R | 2 |
| de la Rubia, J | 2 |
| Martín, A | 1 |
| Bladé, J | 10 |
| Lahuerta, JJ | 3 |
| Orfao, A | 1 |
| San Miguel, JF | 4 |
| Licci, S | 1 |
| Narciso, P | 1 |
| McCann, S | 2 |
| Schwenkglenks, M | 2 |
| Bacon, P | 2 |
| D'Addio, A | 2 |
| Maertens, J | 2 |
| Niederwieser, D | 2 |
| Rabitsch, W | 2 |
| Roosaar, A | 2 |
| Ruutu, T | 2 |
| Schouten, H | 2 |
| Stone, R | 2 |
| Vorkurka, S | 1 |
| Quinn, B | 2 |
| Blijlevens, N | 2 |
| Barlogie, B | 5 |
| Epstein, J | 1 |
| Shaughnessy, JD | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Kyle, RA | 14 |
| Jacobus, S | 1 |
| Friedenberg, WR | 1 |
| Slabber, CF | 1 |
| Rajkumar, SV | 1 |
| Greipp, PR | 6 |
| Chen, AI | 1 |
| Negrin, RS | 1 |
| McMillan, A | 1 |
| Shizuru, JA | 1 |
| Johnston, LJ | 1 |
| Lowsky, R | 1 |
| Miklos, DB | 1 |
| Arai, S | 1 |
| Weng, WK | 1 |
| Laport, GG | 1 |
| Stockerl-Goldstein, K | 1 |
| Waśko-Grabowska, A | 1 |
| Rzepecki, P | 1 |
| Oborska, S | 1 |
| Barzał, J | 1 |
| Gawroński, K | 1 |
| Młot, B | 1 |
| Szczylik, C | 1 |
| Moreau, P | 1 |
| Misbahi, R | 1 |
| Milpied, N | 1 |
| Morineau, N | 1 |
| Mahé, B | 1 |
| Vigier, M | 1 |
| Rapp, MJ | 1 |
| Bataille, R | 3 |
| Harousseau, JL | 4 |
| Shuttleworth, GN | 1 |
| Cook, SD | 1 |
| Ropner, JE | 1 |
| García, J | 1 |
| Lizasoain, M | 1 |
| Sanz, F | 1 |
| Child, JA | 2 |
| Morgan, GJ | 2 |
| Davies, FE | 2 |
| Owen, RG | 1 |
| Bell, SE | 1 |
| Hawkins, K | 1 |
| Brown, J | 1 |
| Drayson, MT | 1 |
| Selby, PJ | 2 |
| Dasgupta, RK | 1 |
| Adamson, PJ | 1 |
| Rollinson, S | 1 |
| Roddam, PL | 1 |
| Ashcroft, AJ | 1 |
| Dring, AM | 1 |
| Fenton, JA | 1 |
| Allan, JM | 1 |
| Hungria, VT | 1 |
| Latrilha, MC | 1 |
| Rodrigues, DG | 1 |
| Bydlowski, SP | 1 |
| Chiattone, CS | 1 |
| Maranhão, RC | 1 |
| De Rosa, L | 1 |
| Anghel, G | 1 |
| Pandolfi, A | 1 |
| Riccardi, M | 1 |
| Amodeo, R | 1 |
| Majolino, I | 1 |
| Rao, PS | 1 |
| Rosiñol, L | 1 |
| Ribera, JM | 3 |
| Díaz-Mediavilla, J | 1 |
| García-Laraña, J | 2 |
| Fernández-Calvo, J | 2 |
| Martí, JM | 3 |
| Giraldo, P | 1 |
| Carbonell, F | 2 |
| Callís, M | 1 |
| Trujillo, J | 2 |
| Gardella, S | 3 |
| Moro, MJ | 5 |
| Barez, A | 1 |
| Soler, A | 1 |
| Font, L | 2 |
| Fontanillas, M | 5 |
| San Miguel, J | 5 |
| Strobel, ES | 1 |
| Bauchmüller, K | 2 |
| Schmitt-Gräff, A | 1 |
| Engelhardt, M | 2 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 3 |
| Sastry, P | 1 |
| Bhagwat, R | 1 |
| Biswas, G | 1 |
| Khadwal, A | 1 |
| Narayanan, P | 1 |
| Bakshi, A | 1 |
| Parikh, P | 1 |
| Comenzo, RL | 1 |
| Hassoun, H | 1 |
| Kewalramani, T | 1 |
| Klimek, V | 1 |
| Dhodapkar, M | 1 |
| Reich, L | 1 |
| Teruya-Feldstein, J | 1 |
| Fleisher, M | 1 |
| Filippa, D | 1 |
| Nimer, SD | 1 |
| Haas, PS | 1 |
| Kühnemund, A | 1 |
| Finke, J | 1 |
| Ihorst, G | 1 |
| Anderson, KC | 1 |
| Lazarus, HM | 2 |
| Hurd, DD | 1 |
| McCoy, J | 1 |
| Moore, DF | 1 |
| Dakhil, SR | 1 |
| Lanier, KS | 1 |
| Chapman, RA | 1 |
| Cromer, JN | 1 |
| Salmon, SE | 13 |
| Durie, B | 1 |
| Crowley, JC | 1 |
| Assouline, S | 1 |
| Sylvestre, MP | 1 |
| Carriere, P | 1 |
| Shustik, C | 1 |
| Laneuville, P | 1 |
| Leong, T | 3 |
| Li, S | 1 |
| Oken, MM | 6 |
| Kay, NE | 4 |
| Van Ness, B | 3 |
| Hock, BD | 1 |
| Drayson, M | 1 |
| Patton, WN | 1 |
| Taylor, K | 1 |
| Kerr, L | 1 |
| McKenzie, JL | 1 |
| Alegre, A | 1 |
| Fernández, P | 2 |
| de Arriba, F | 1 |
| Besalduch, J | 4 |
| García Boyero, R | 1 |
| Palomera Bernal, L | 1 |
| Hernández, MT | 1 |
| García, PR | 1 |
| Pérez-Calvo, J | 1 |
| Alcalá, A | 6 |
| Casado, LF | 1 |
| Kroschinsky, F | 1 |
| Hölig, K | 1 |
| Platzbecker, U | 1 |
| Poppe-Thiede, K | 1 |
| Ordemann, R | 1 |
| Blechschmidt, M | 1 |
| Oelschlaegel, U | 1 |
| Schaich, M | 1 |
| Hänel, M | 1 |
| Bornhäuser, M | 1 |
| Ehninger, G | 1 |
| Vela-Ojeda, J | 2 |
| García-Ruiz-Esparza, MA | 1 |
| Padilla-González, Y | 1 |
| Gómez-Almaguer, D | 1 |
| Gutiérrez-Aguirre, CH | 1 |
| Gómez-Rangel, D | 1 |
| Morales-Toquero, A | 1 |
| Ruiz-Delgado, GJ | 1 |
| Delgado-Lamas, JL | 1 |
| Ruiz-Argüelles, GJ | 1 |
| Batts, ED | 1 |
| Maisel, C | 1 |
| Kane, D | 1 |
| Liu, L | 1 |
| Fu, P | 1 |
| O'Brien, T | 1 |
| Remick, S | 1 |
| Bahlis, N | 1 |
| Gerson, SL | 1 |
| Yang, X | 1 |
| Yang, C | 1 |
| Shao, K | 1 |
| Ye, X | 1 |
| Meng, H | 1 |
| Zhou, Y | 1 |
| Qian, W | 1 |
| Vokurka, S | 1 |
| Bonnet, JD | 2 |
| Alexanian, R | 5 |
| Haut, A | 3 |
| Dixon, DO | 2 |
| Dreicer, R | 1 |
| Morstyn, G | 1 |
| Schechter, GP | 1 |
| Ihde, DC | 1 |
| Carney, DN | 1 |
| Eddy, JL | 1 |
| Cohen, MH | 1 |
| Minna, JD | 1 |
| Bunn, PA | 1 |
| Adelstein, DJ | 1 |
| Herzig, RH | 1 |
| Smith, MC | 1 |
| Cohen, HJ | 5 |
| Silberman, HR | 3 |
| Tornyos, K | 1 |
| Bartolucci, AA | 3 |
| Steinke, B | 2 |
| Busch, FW | 2 |
| Stapelfeld, S | 1 |
| Ostendorf, P | 2 |
| Waller, HD | 2 |
| Gössinger, H | 1 |
| Bettelheim, P | 1 |
| Neumann, E | 1 |
| Hinterberger, W | 1 |
| Korninger, K | 1 |
| Niessner, H | 1 |
| Pabinger-Fasching, I | 1 |
| Bauer, K | 1 |
| Lechner, K | 1 |
| Iwata, Y | 1 |
| Karitani, Y | 1 |
| Tanaka, I | 1 |
| Kobayashi, T | 1 |
| Ohno, T | 1 |
| Kageyama, S | 1 |
| Katayama, N | 1 |
| Kataoka, Y | 1 |
| Kamio, N | 1 |
| Ohota, C | 1 |
| Montalbán, C | 2 |
| Zapatero, A | 2 |
| Blanco, L | 2 |
| Sevilla, F | 2 |
| García Laraña, J | 1 |
| Odriozola, J | 1 |
| Paccagnella, A | 2 |
| Cartei, G | 1 |
| Fosser, V | 1 |
| Salvagno, L | 2 |
| Bolzonella, S | 2 |
| Chiarion Sileni, V | 1 |
| Fiorentino, MV | 1 |
| Weiss, RB | 1 |
| Issell, BF | 1 |
| Tirelli, U | 1 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Veronesi, A | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Case, DC | 4 |
| Snigurowicz, J | 1 |
| Kraj, M | 3 |
| Rostkowska, J | 3 |
| Maj, S | 3 |
| Mariańska, B | 1 |
| Mendek, E | 1 |
| Roszkowski, S | 1 |
| Kilian, Z | 1 |
| Kołakowski, L | 1 |
| Tribalto, M | 4 |
| Arcese, W | 1 |
| Colombo, R | 1 |
| Pastore, S | 1 |
| Franchii, A | 1 |
| Broun, GO | 1 |
| Petruska, PJ | 1 |
| Hiramoto, RN | 2 |
| Abramson, N | 2 |
| Lurie, P | 1 |
| Mietlowski, WL | 1 |
| Schilling, A | 1 |
| Bennett, JM | 1 |
| Horton, J | 1 |
| Bonnet, J | 3 |
| Salmon, S | 2 |
| Bottomley, R | 1 |
| Amare, M | 1 |
| Dixon, D | 1 |
| Pajak, TF | 6 |
| Henderson, ES | 1 |
| Nawabi, IU | 1 |
| Brunner, K | 3 |
| Henry, PH | 1 |
| McIntyre, OR | 8 |
| Holland, JF | 2 |
| Cornwell, GG | 3 |
| Kochwa, S | 4 |
| Glowienka, LP | 2 |
| Rafla, S | 3 |
| Silver, RT | 1 |
| Cooper, MR | 4 |
| Henderson, E | 2 |
| Haurani, FI | 1 |
| Cuttner, J | 2 |
| Hofmann, V | 1 |
| Durie, BG | 5 |
| Morlock, G | 1 |
| Rosenberg, F | 1 |
| Lopitaux, R | 1 |
| Blotman, F | 1 |
| Sany, J | 1 |
| Ciurana, AJ | 1 |
| Rampon, S | 1 |
| Bussière, JL | 1 |
| Simon, L | 1 |
| Serre, H | 1 |
| Sedlácková, M | 1 |
| Ghosh, K | 1 |
| Sivakumaran, M | 1 |
| Murphy, P | 1 |
| Chapman, CS | 1 |
| Wood, JK | 1 |
| Roldán, V | 1 |
| García, MC | 1 |
| Gil, MT | 1 |
| Rivas, C | 1 |
| Guillemin, F | 1 |
| Guerci, AP | 1 |
| Feugier, P | 1 |
| Péré, P | 1 |
| Pourel, J | 1 |
| Guerci, O | 1 |
| Peest, D | 5 |
| Deicher, H | 5 |
| Coldewey, R | 3 |
| Leo, R | 2 |
| Bartl, R | 2 |
| Bartels, H | 2 |
| Braun, HJ | 2 |
| Fett, W | 1 |
| Fischer, JT | 2 |
| Göbel, B | 1 |
| Colović, MD | 1 |
| Janković, GM | 1 |
| Nikolov, VS | 1 |
| Suvajdzić, ND | 1 |
| Miletić, VD | 1 |
| Adkins, DR | 1 |
| Salzman, D | 1 |
| Boldt, D | 1 |
| Kuhn, J | 1 |
| Irvin, R | 1 |
| Roodman, GD | 1 |
| Lyons, R | 1 |
| Smith, L | 1 |
| Freytes, CO | 1 |
| LeMaistre, CF | 2 |
| Crowley, JJ | 1 |
| Grogan, TM | 1 |
| Finley, P | 2 |
| Pugh, RP | 2 |
| Barbot, C | 1 |
| Rice, A | 1 |
| Vanès, I | 1 |
| Mahon, FX | 1 |
| Jazwiec, B | 1 |
| Reiffers, J | 1 |
| Delain, M | 1 |
| Linassier, C | 1 |
| Petitdidier, C | 1 |
| Goupille, P | 1 |
| Luthier, F | 1 |
| Combe, M | 1 |
| Reisenleiter, M | 1 |
| Benboubker, L | 1 |
| Lamagnère, JP | 1 |
| Colombat, P | 1 |
| Gola, A | 2 |
| Usnarska-Zubkiewicz, L | 2 |
| Wołowiec, D | 1 |
| Urbaniak-Kujda, D | 1 |
| Kotlarek-Haus, S | 1 |
| Meerkin, D | 1 |
| Ashkenazi, Y | 1 |
| Gottschalk-Sabag, S | 1 |
| Hershko, C | 1 |
| Maldonado, J | 4 |
| Sanz, MA | 1 |
| García-Conde, J | 6 |
| Alonso, C | 2 |
| Zubizarreta, A | 2 |
| Kuliszkiewicz-Janus, M | 1 |
| Baczyński, S | 1 |
| Modiano, MR | 1 |
| Villar-Werstler, P | 1 |
| Crowley, J | 3 |
| Attal, M | 3 |
| Stoppa, AM | 1 |
| Sotto, JJ | 2 |
| Fuzibet, JG | 1 |
| Rossi, JF | 1 |
| Casassus, P | 1 |
| Maisonneuve, H | 1 |
| Facon, T | 1 |
| Ifrah, N | 1 |
| Payen, C | 1 |
| Ager, S | 1 |
| Mahendra, P | 1 |
| Richards, EM | 1 |
| Bass, G | 1 |
| Baglin, TP | 1 |
| Marcus, RE | 1 |
| Tsiatis, A | 1 |
| Gregory, SA | 1 |
| Spiegel R, J | 1 |
| O'Connell M, J | 1 |
| Liu, P | 1 |
| Quam, L | 1 |
| Billadeau, D | 1 |
| Greipp, P | 1 |
| Muñoz, M | 1 |
| Besses, C | 3 |
| Rozman, C | 4 |
| Montserrat, E | 4 |
| Estapé, J | 3 |
| Boccadoro, M | 5 |
| Palumbo, A | 1 |
| Argentino, C | 1 |
| Dominietto, A | 1 |
| Frieri, R | 2 |
| Avvisati, G | 3 |
| Comotti, B | 3 |
| Lauta, VM | 2 |
| Liberati, M | 2 |
| Marmont, F | 4 |
| Musto, P | 1 |
| Pileri, A | 3 |
| Keimowitz, RM | 2 |
| Harrington, DP | 1 |
| Knospe, W | 1 |
| Glick, JH | 1 |
| Joshua, DE | 1 |
| Penny, R | 1 |
| Matthews, JP | 1 |
| Laidlaw, CR | 1 |
| Gibson, J | 1 |
| Bradstock, K | 1 |
| Wolf, M | 1 |
| Goldstein, D | 1 |
| Varterasian, M | 1 |
| Janakiraman, N | 1 |
| Karanes, C | 1 |
| Abella, E | 1 |
| Uberti, J | 1 |
| Dragovic, J | 1 |
| Raman, SB | 1 |
| al-Katib, A | 1 |
| Du, W | 1 |
| Silver, SM | 1 |
| Adams, PT | 1 |
| Sensenbrenner, L | 1 |
| Sokołowska, B | 2 |
| Dmoszyńska, A | 2 |
| Walter-Croneck, A | 1 |
| Wojtaszko, M | 1 |
| Yen, CC | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Fang, FS | 1 |
| Wang, WS | 1 |
| Tung, SL | 1 |
| Tzeng, CH | 1 |
| Chen, PM | 1 |
| Escudero, ML | 2 |
| Arias, J | 1 |
| Carnero, M | 2 |
| Drach, J | 1 |
| Ackermann, J | 1 |
| Fritz, E | 1 |
| Krömer, E | 1 |
| Schuster, R | 1 |
| Gisslinger, H | 1 |
| DeSantis, M | 1 |
| Zojer, N | 1 |
| Fiegl, M | 1 |
| Roka, S | 1 |
| Schuster, J | 1 |
| Heinz, R | 1 |
| Ludwig, H | 1 |
| Huber, H | 1 |
| Mineur, P | 1 |
| Ménard, JF | 2 |
| Le Loët, X | 2 |
| Bernard, JF | 2 |
| Grosbois, B | 2 |
| Pollet, JP | 2 |
| Azais, I | 2 |
| Laporte, JP | 2 |
| Doyen, C | 2 |
| De Gramont, A | 1 |
| Wetterwald, M | 1 |
| Euller-Ziegler, L | 1 |
| Peny, AM | 1 |
| Monconduit, M | 2 |
| Michaux, JL | 2 |
| Gertz, MA | 1 |
| Lacy, MQ | 2 |
| Inwards, DJ | 2 |
| Chen, MG | 1 |
| Pineda, AA | 1 |
| Gastineau, DA | 1 |
| Lust, JA | 1 |
| Tefferi, A | 1 |
| Witzig, TE | 1 |
| Litzow, MR | 1 |
| Kiss, I | 1 |
| Tomasek, J | 1 |
| Biriukova, LS | 1 |
| Volodiaeva, EB | 1 |
| Fetisova, EV | 1 |
| Pivnik, AV | 1 |
| Margolin, OV | 1 |
| Dix, S | 1 |
| Cord, M | 1 |
| Howard, S | 1 |
| Coon, J | 1 |
| Belt, R | 1 |
| Geller, R | 1 |
| Lenhard, RE | 1 |
| Sanchis-Bayarri Bernal, V | 1 |
| García Gascó, P | 1 |
| Tordera Higón, P | 1 |
| Micó Giner, L | 1 |
| Calabuig Alborch, JR | 1 |
| Sirohi, B | 1 |
| Powles, R | 1 |
| Treleaven, J | 1 |
| Mainwaring, P | 1 |
| Kulkarni, S | 1 |
| Pandha, H | 1 |
| Bhagwati, N | 1 |
| Horton, C | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Tripp-Villanueva, F | 1 |
| Montiel-Cervantes, L | 1 |
| Sánchez-Cortés, E | 1 |
| Ayala-Sánchez, M | 1 |
| Guevara-Moreno, ME | 1 |
| García-León, LD | 1 |
| Rosas-Cabral, A | 1 |
| Esparza, MA | 1 |
| González-Llaven, J | 1 |
| Clark, RE | 1 |
| Flory, AJ | 1 |
| Ion, EM | 1 |
| Woodcock, BE | 1 |
| Durham, BH | 1 |
| Fraser, WD | 1 |
| Protheroe, AS | 1 |
| Pickard, C | 1 |
| Johnson, PW | 1 |
| Craddock, T | 1 |
| Shefta, J | 1 |
| Short, K | 1 |
| Lancaster, F | 1 |
| Henwood, J | 1 |
| Boylston, AW | 1 |
| Zervas, K | 1 |
| Pouli, A | 1 |
| Gregoraki, B | 1 |
| Anagnostopoulos, N | 1 |
| Dimopoulos, MA | 1 |
| Bourantas, K | 1 |
| Tzilianos, M | 1 |
| Barbarousi, D | 1 |
| Venetis, E | 1 |
| Vyniou, N | 1 |
| Maniatis, A | 1 |
| Fassas, A | 1 |
| Gojo, I | 1 |
| Rapoport, A | 1 |
| Cottler-Fox, M | 1 |
| Meisenberg, B | 1 |
| Papadimitriou, JC | 1 |
| Tricot, G | 1 |
| Porrata, LF | 1 |
| Markovic, SN | 1 |
| Garban, F | 1 |
| Gallagher, M | 1 |
| Jouvin-Marche, E | 1 |
| Jacob, MC | 1 |
| Moine, A | 1 |
| Marche, PN | 1 |
| Esteve, J | 1 |
| Brunet, S | 2 |
| Conde, E | 1 |
| Hernández-Martín, J | 1 |
| Ortega, F | 2 |
| Alberts, DS | 2 |
| Hamburger, AW | 2 |
| Soehnlen, B | 1 |
| Moon, TE | 1 |
| Foa, J | 1 |
| Carcassonne, Y | 1 |
| Presant, CA | 2 |
| Klahr, C | 2 |
| Santala, R | 1 |
| Tortarolo, M | 2 |
| Cantore, N | 1 |
| Russolillo, S | 2 |
| Castaldo, C | 2 |
| Buonanno, G | 2 |
| Valente, A | 1 |
| Gonnella, F | 1 |
| Harley, JB | 1 |
| Coleman, M | 3 |
| Larsen, WE | 1 |
| Johnson, L | 1 |
| Durant, JR | 3 |
| Gailani, S | 1 |
| Seligman, BR | 1 |
| Blom, J | 1 |
| Bergsagel, DE | 4 |
| Bailey, AJ | 1 |
| Langley, GR | 1 |
| MacDonald, RN | 1 |
| White, DF | 1 |
| Miller, AB | 1 |
| Miller, S | 1 |
| Perrotta, AL | 1 |
| Schorer, AE | 1 |
| Johnson, GJ | 1 |
| Gehan, E | 1 |
| Weick, J | 1 |
| Lee, DJ | 1 |
| Clarkson, BD | 2 |
| Solomon, A | 2 |
| Lennan, RM | 1 |
| Taylor, HR | 1 |
| Elveback, LR | 1 |
| Pruzanski, W | 1 |
| McLaughlin, CL | 1 |
| Capra, JD | 1 |
| Ghanta, VK | 1 |
| Jones, MT | 1 |
| Woodard, DA | 1 |
| Obrecht, JP | 1 |
| Sieber, SM | 1 |
| Adamson, RH | 1 |
| Hiramoto, R | 1 |
| Ghanta, V | 1 |
| MacLennan, IC | 1 |
| Chapman, C | 1 |
| Dunn, J | 2 |
| Kelly, K | 1 |
| Clarke, M | 1 |
| Gray, R | 1 |
| MacLennan, I | 1 |
| Futscher, BW | 1 |
| Campbell, K | 1 |
| Dalton, WS | 1 |
| Pais, JR | 1 |
| Pascual, J | 1 |
| Pérez Vaquero, MA | 1 |
| Hernando, JC | 1 |
| Sanz-Sanz, MA | 1 |
| Hernández, JM | 1 |
| Martínez, M | 1 |
| Moro, J | 1 |
| Kuliczkowski, K | 1 |
| Sedek, K | 1 |
| Shimamoto, Y | 1 |
| Matsuzaki, M | 1 |
| Ono, K | 1 |
| Sano, M | 1 |
| Yamaguchi, M | 1 |
| Raya Sánchez, JM | 1 |
| González Brito, G | 1 |
| Marsá Vila, L | 1 |
| Brito Barroso, ML | 1 |
| Hernández Nieto, L | 1 |
| Mendek-Czajkowska, E | 2 |
| Pogłód, R | 2 |
| Sabliński, J | 1 |
| Kowalewski, J | 1 |
| Kurowska, M | 1 |
| Sokołowska, U | 1 |
| Golenkov, AK | 1 |
| Chiarion-Sileni, V | 1 |
| Soesan, M | 1 |
| Baggio, G | 1 |
| De Besi, P | 1 |
| Casara, D | 1 |
| Frizzarin, M | 1 |
| Favaretto, A | 1 |
| Beckord, J | 1 |
| Ventura, GJ | 1 |
| Hester, JP | 1 |
| Yau, JC | 1 |
| Wallerstein, RO | 1 |
| Spinolo, JA | 1 |
| Dicke, KA | 1 |
| Horwitz, LH | 1 |
| Andriani, A | 1 |
| Barbui, T | 2 |
| Cantonetti, M | 3 |
| Carotenuto, M | 1 |
| Dammacco, F | 3 |
| von Broen, IM | 2 |
| Gramatzki, M | 2 |
| Tesh, D | 1 |
| Saeed, S | 1 |
| Milder, MS | 1 |
| Hutchins, LF | 1 |
| Coltman, CA | 1 |
| Cheson, B | 1 |
| Hjorth, M | 1 |
| Hellquist, L | 1 |
| Holmberg, E | 1 |
| Magnusson, B | 1 |
| Rödjer, S | 1 |
| Westin, J | 1 |
| Cammerer, U | 1 |
| Hein, R | 1 |
| Hoffmann, L | 1 |
| Konyar, H | 1 |
| Kreuser, ED | 1 |
| Selbach, J | 1 |
| Sanz Sanz, MA | 1 |
| van Hoeven, KH | 1 |
| Reed, LJ | 1 |
| Factor, SM | 1 |
| Cavo-Comotti, BM | 1 |
| Gallamini, A | 2 |
| Gallone, G | 1 |
| Uzuka, Y | 2 |
| Saito, Y | 2 |
| Ito, T | 2 |
| Fermand, JP | 1 |
| Lévy, Y | 1 |
| Gerota, J | 1 |
| Benbunan, M | 1 |
| Cosset, JM | 1 |
| Castaigne, S | 1 |
| Seligmann, M | 1 |
| Brouet, JC | 1 |
| Osterborg, A | 1 |
| Ahre, A | 1 |
| Björkholm, M | 1 |
| Björeman, M | 1 |
| Brenning, G | 1 |
| Gahrton, G | 1 |
| Gyllenhammar, H | 1 |
| Johansson, B | 1 |
| Juliusson, G | 1 |
| Järnmark, M | 1 |
| Neretto, G | 1 |
| Petrucci, MT | 1 |
| Resegotti, L | 1 |
| Takahashi, H | 1 |
| Komatsu, M | 1 |
| Ishii, H | 1 |
| Bury, J | 1 |
| Salmon, J | 1 |
| Fillet, G | 1 |
| Cavo, M | 2 |
| Galieni, P | 1 |
| Tassi, C | 1 |
| Tura, S | 2 |
| Schmoll, HJ | 2 |
| Schedel, I | 2 |
| Glück, S | 2 |
| Schumacher, K | 1 |
| Baccarani, M | 1 |
| Ricci, P | 1 |
| Forman, WB | 1 |
| Sakalová, A | 1 |
| Hrubisko, M | 1 |
| Gazová, S | 1 |
| Steruská, M | 1 |
| Prümmerová, J | 1 |
| Carter, S | 1 |
| Stephens, R | 1 |
| Rivkin, S | 1 |
| Dabich, L | 1 |
| Files, JC | 1 |
| Costanzi, JJ | 1 |
| Propert, KJ | 1 |
| Anderson, K | 1 |
| Prager, D | 1 |
| Zimmer, B | 1 |
| Boll, J | 1 |
| Essers, U | 1 |
| Gamm, H | 1 |
| Görg, K | 1 |
| Kildahl-Andersen, O | 1 |
| Bjark, P | 1 |
| Bondevik, A | 1 |
| Bull, O | 1 |
| Dehli, O | 1 |
| Kvambe, V | 1 |
| Nordahl, E | 1 |
| Ytrehus, K | 1 |
| Lamvik, J | 1 |
| van Dijk, JM | 1 |
| Sonnenblick, M | 1 |
| Weissberg, N | 1 |
| Rosin, A | 1 |
| Ho, AD | 1 |
| Wittkamp, S | 1 |
| Theml, H | 1 |
| Keilholz, U | 1 |
| Hunstein, W | 1 |
| Cervantes, F | 1 |
| Feliu, E | 1 |
| Grañena, A | 1 |
| Marín, P | 1 |
| Nomdedeu, B | 1 |
| Becherer, C | 1 |
| Sabán, J | 1 |
| Serrano, M | 1 |
| Serrano Ríos, M | 1 |
| Sonneborn, HL | 1 |
| Paul, SD | 1 |
| Hayes, DM | 1 |
| Dorsk, BM | 1 |
| Carroll, RJ | 1 |
| Bove, L | 1 |
| Bartolucci, A | 1 |
| Amadori, S | 1 |
| Franchi, A | 1 |
| Papa, G | 1 |
| Vacca, A | 1 |
| Centurioni, R | 1 |
| Hansen, OP | 1 |
| Clausen, NA | 1 |
| Drivsholm, A | 1 |
| Laursen, B | 1 |
| Estivill, X | 1 |
| Puig, J | 1 |
| Domingo-Albós, A | 1 |
| Leone, L | 1 |
| Frei, E | 1 |
| Schabel, FM | 1 |
| Goldin, A | 1 |
| Sonntag, R | 1 |
| Favre, E | 1 |
| Martz, G | 1 |
| Carter, SK | 1 |
| Azam, L | 2 |
| Delamore, IW | 2 |
| Lee, BJ | 1 |
| Sahakian, G | 1 |
| Krakoff, IH | 1 |
| Teller, MN | 1 |
| Bowie, M | 1 |
| Mountain, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Resp[NCT00560053] | Phase 3 | 500 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma[NCT00349778] | Phase 2 | 102 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| Clinical Study of Anti-CD19/BCMA Bispecific Chimeric Antigen Receptors (CARs) T Cell Therapy for Relapsed and Refractory Multiple Myeloma[NCT03706547] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-10-30 | Not yet recruiting | ||
| Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction[NCT03516903] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2018-04-17 | Terminated (stopped due to Due to the COVID-19 pandemic. With a second wave just beginning, and considering that we are testing an immunosuppressant in patients with high risk for COVID-19 complications, we would not be able to re-start recruitment safely in the near future.) | ||
| Standard Dose Versus Myeloablative Therapy for Previously Untreated Symptomatic Multiple Myeloma, A Phase III Intergroup Study[NCT00002548] | Phase 3 | 899 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients.[NCT00391157] | Phase 2 | 40 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [NCT00222053] | Phase 3 | 800 participants (Actual) | Interventional | 2000-04-30 | Completed | ||
| A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation.[NCT02791373] | Phase 2 | 136 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma[NCT01207765] | Phase 2 | 8 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to changes in practice) | ||
| A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma[NCT02416206] | Phase 2 | 65 participants (Actual) | Interventional | 2015-04-27 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| HIGH-DOSE MELPHALAN CHEMOTHERAPY AND TOTAL BODY RADIATION WITH PERIPHERAL BLOOD STEM-CELL RECONSTITUTION FOR PATIENTS WITH RELAPSING MULTIPLE MYELOMA[NCT00002630] | Phase 2 | 50 participants (Anticipated) | Interventional | 1993-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Relapse was measured as the number of patients who relapse after high-dose sequential therapy then autologous transplantation (NCT00349778)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-Dose Sequential Therapy | 66 |
Pulmonary toxicity was assessed as the incidence of interstitial pneumonitis. (NCT00349778)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-Dose Sequential Therapy | 32 |
Survival status was assessed 5 years after transplant. (NCT00349778)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| High-Dose Sequential Therapy | 52 |
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
Number of days from stem cell infusion (day +0) to day of neutrophil engraftment (first of three consecutive days with absolute neutrophil count > 500) (NCT01207765)
Timeframe: Transplant through day 42
| Intervention | Days (Median) |
|---|---|
| Zevalin | 13 |
Efficacy: objective response rate (CR + PR) at 12 and 104 days following radioimmunotherapy. Safety: the rate of occurrence of defined toxic events including non-engraftment and unacceptable biodistribution of 90Y Zevalin occurring by day +42 following transplant. Response determined according to Blade' Criteria (Bladé J, Br J Haematol.1998 Sep;102(5):1115-23) for multiple myeloma; Response based on reduction of monoclonal protein (M-protein) from initial presentation. (NCT01207765)
Timeframe: Through day +104 following immunotherapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| CR/PR at +12 days | CR/PR at +104 days | Participants with toxic events | |
| Zevalin | 1 | 5 | 5 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 28 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 60 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 37 |
10 reviews available for carmustine and Multiple Myeloma
| Article | Year |
|---|---|
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod | 1982 |
[Chemotherapy of multiple myeloma. Review of the recent trials].
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combi | 1981 |
Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Diagnosis, Diffe | 1994 |
[Treatment of Kahler's disease].
Topics: Bone Neoplasms; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple | 1976 |
[Recent progress in chemotherapy of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; | 1978 |
Current concepts in cancer. Multiple myeloma.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunoglobul | 1979 |
The treatment of plasma cell myeloma.
Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Me | 1976 |
[Chemotherapy of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Eval | 1991 |
Plasma cell myeloma. An interpretive review.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Carmustine; Cell Division; Cyclophosphamide; Drug Re | 1972 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
86 trials available for carmustine and Multiple Myeloma
| Article | Year |
|---|---|
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Fr | 2020 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmust | 2014 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-Free Survival; | 2009 |
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Disease-Free Survival; Femal | 2012 |
Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Phosphates; Carmustine; Cytarabine; E | 2011 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2003 |
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Case-Control Studies; Cyclo | 2003 |
Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cel | 2004 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Dose-Re | 2005 |
Trial of amifostine in autologous stem cell transplant.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cy | 2006 |
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2006 |
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 2006 |
Circulating levels and clinical significance of soluble CD86 in myeloma patients.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; Bioma | 2006 |
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
Topics: Adult; Age Factors; Aged; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2006 |
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; | 2006 |
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Drug Administration Sc | 2007 |
Chemotherapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1984 |
Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1984 |
Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcium Gluconate; Carmustine; Clini | 1984 |
[Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; | 1984 |
Chemotherapy of plasma-cell myeloma.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan | 1980 |
Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug The | 1981 |
Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bone Marrow; Carmustine; Cisplatin; Clinical Trials as | 1982 |
Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr | 1982 |
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials a | 1982 |
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap | 1982 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Development of a criterion for response to therapy at 6 months in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; D | 1995 |
A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1994 |
Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; | 1994 |
VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1994 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1993 |
Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229.
Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Carmustine; Cohort Studies; Cyclophosp | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Comb | 1996 |
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cycloph | 1996 |
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Clone Cells; C | 1996 |
Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclo | 1996 |
Standard therapy versus autologous transplantation in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cross-Ov | 1997 |
Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1997 |
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1997 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpla | 1998 |
Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosph | 1998 |
[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease P | 1998 |
VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1998 |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Disea | 1999 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chem | 2000 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc | 2000 |
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized stud
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2001 |
Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cyclophosphamide; Dose-R | 2001 |
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melp | 1979 |
Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Topics: Carmustine; Cyclophosphamide; Drug Resistance; Drug Therapy, Combination; Humans; Melphalan; Multipl | 1979 |
The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combinati | 1979 |
Combination therapy for multiple myeloma.
Topics: Antineoplastic Agents; Azathioprine; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combin | 1977 |
Nitrosoureas in multiple myeloma.
Topics: Carmustine; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Human | 1976 |
Remission maintenance therapy for multiple myeloma.
Topics: Bone Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; | 1975 |
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cause of Dea | 1992 |
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cause of Dea | 1992 |
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cause of Dea | 1992 |
Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cause of Dea | 1992 |
VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexametha | 1992 |
[Therapeutic plasmapheresis in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1991 |
[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubic | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
Second and third responses to the same induction regimen in relapsing patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; F | 1991 |
alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorub | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Carmustine; Cyclophospha | 1991 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatmen
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dexamethasone | 1990 |
Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Carmustine; | 1990 |
Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1990 |
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Female; Foll | 1990 |
A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Drug Admi | 1990 |
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical | 1989 |
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Cycle; Cyclophosphamid | 1989 |
Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Drug Administr | 1988 |
Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Carmustine; Clinical Trials as Topic; | 1986 |
Results and further perspectives of plasmocytoma chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trial | 1986 |
Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1986 |
Current results of a multicenter trial in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 1986 |
Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trial | 1985 |
Treatment of multiple myeloma: a randomized study of three different regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as | 1985 |
Phase III study of intermittent 5-drug regimen (VBCMP) versus intermittent 3-drug regimen (VMP) versus intermittent melphalan and prednisone (MP) in myelomatosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Response rate and survival in myeloma patients receiving prednisone alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Male; Melphalan; Middle | 1985 |
[Therapeutic experiences in multiple myeloma].
Topics: Aniline Compounds; Antineoplastic Agents; Blood Sedimentation; Carmustine; Clinical Trials as Topic; | 1972 |
Combination therapy for myelomatosis.
Topics: Bone Marrow Examination; Calcium; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Drug Thera | 1974 |
106 other studies available for carmustine and Multiple Myeloma
| Article | Year |
|---|---|
Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Cyclophosphami | 2023 |
High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Hematopoietic Stem Cell Transpla | 2018 |
[The significance of expression of isoforms RARa1 and RARa2 in response to medicinal therapy and in evaluation of total survival of patients with primarily detected multiple myeloma].
Topics: Adult; Aged; Apoptosis; Biomarkers, Pharmacological; Carmustine; Disease-Free Survival; Female; Gene | 2016 |
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Disease | 2014 |
Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Topics: Adult; Biosimilar Pharmaceuticals; Carmustine; Female; Filgrastim; Granulocyte Colony-Stimulating Fa | 2014 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Su | 2015 |
Myelomatous meningitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 2008 |
The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
Topics: Adult; Aged; Analgesics, Opioid; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Going with the flow, and beyond, in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2002 |
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxo | 2002 |
[Bacteremia due to Capnocytophaga spp.: two cases].
Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremi | 2003 |
Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Combined Modality | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Su | 2006 |
Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dis | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Tri | 2007 |
Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine | 2008 |
In vitro cloning and chemosensitivity of human myeloma stem cells.
Topics: Animals; Carmustine; Cell Transformation, Neoplastic; Clone Cells; Colony-Forming Units Assay; DNA; | 1982 |
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Doxorubicin; Drug | 1984 |
Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cy | 1983 |
[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Creatinine; Cyclophosphamid | 1984 |
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Therapy, Co | 1984 |
[Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1984 |
Treatment of multiple myeloma with M-2 protocol and without maintenance therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 1983 |
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycl | 1982 |
Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
Topics: Carmustine; Cell Nucleus; Cell Transformation, Neoplastic; Doxorubicin; Drug Resistance; Drug Therap | 1981 |
[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Adminis | 1980 |
Therapy of myeloma.
Topics: Carmustine; Cyclophosphamide; Humans; Multiple Myeloma; Prednisone | 1980 |
[Multiple myeloma treatment with adriablastin and BCNU (author's transl)].
Topics: Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Humans; Middle Aged; Multiple Myelo | 1980 |
Visual hallucinations following treatment with vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin | 1994 |
[Pneumonia caused by Salmonella in a patient with myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dexamethasone; Doxorub | 1995 |
The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1994 |
Quality and functional capacity of the bone marrow microenvironment of autologous blood stem cell transplantation (ABSCT) recipients.
Topics: Bone Marrow; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Connective Tissue; Cyclophosph | 1994 |
[Results of alternating treatment of multiple myeloma--cytostatics VBMCP and recombinant interferon alfa-2B].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; H | 1993 |
Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium; Carmustine; Cholesterol; Cyclo | 1995 |
High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1996 |
Conventional induction treatments do not influence overall survival in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1997 |
Dementia improvement with cytotoxic chemotherapy. A case of Alzheimer disease and multiple myeloma.
Topics: Alzheimer Disease; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Hum | 1997 |
[The influence of verapamil on platelet function in patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Fem | 1997 |
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Chromosomes, Human, | 1998 |
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bone Marrow; Carm | 1999 |
Sodium and potassium excretion changes and bone marrow recovery after chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; | 1999 |
[Acute and chronic renal failure in patients with myeloma].
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophospham | 1999 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1999 |
[Lumbago radiating to the right leg as a form of onset of multiple myeloma in a 33-year-old patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Doxoru | 1999 |
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom | 2000 |
Persistence of clonal T-cell expansions following high-dose chemotherapy and autologous peripheral blood progenitor cell rescue.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Bone Marrow Purging; Breast Neoplasms; Carci | 2000 |
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Thera | 2001 |
[Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 2001 |
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protoco | 2001 |
Immunotherapy by non-myeloablative stem cell transplantation: study of the immune reconstitution. Arguments for distinct cell subsets in skin and blood.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blood; Blood Cells; Carmustine; CD8-P | 2000 |
Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse.
Topics: Alkylating Agents; Blood Cell Count; Carmustine; Cell Count; Doxorubicin; Drug Therapy, Combination; | 1976 |
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Clone Cells; Doxorubicin; Drug Resistance; Female; Hem | 1978 |
Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
Topics: Adult; Aged; Amphotericin B; Breast Neoplasms; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resis | 1977 |
Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
Topics: Adult; Aged; Alkylating Agents; Carmustine; Cyclophosphamide; Drug Evaluation; Drug Resistance; Drug | 1978 |
Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Multiple Mye | 1979 |
Multiple myeloma: results with the M-2 protocol in a community hospital.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Hospitals, Community | 1979 |
Gynecomastia with nitrosourea therapy.
Topics: Adult; Aged; Carmustine; Gynecomastia; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 1978 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immu | 1977 |
Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.
Topics: Adult; Aged; Bence Jones Protein; Carmustine; Cyclophosphamide; Female; Humans; Male; Melphalan; Mid | 1978 |
Optic neuroretinitis in association with BCNU and procarbazine therapy.
Topics: Carmustine; Drug Therapy, Combination; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple My | 1978 |
Carmustine (BiCNU).
Topics: Brain Neoplasms; Carmustine; Hodgkin Disease; Humans; Lymphoma; Multiple Myeloma | 1978 |
A new basis for treatment of multiple myeloma.
Topics: Carmustine; Cell Transformation, Neoplastic; Doxorubicin; Drug Resistance; Humans; Melphalan; Multip | 1978 |
Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance | 1978 |
Management and prognosis of multiple myeloma.
Topics: Anemia; Bacterial Infections; BCG Vaccine; Carmustine; Cyclophosphamide; Fractures, Bone; Humans; Hy | 1976 |
Treatment of plasma cell myeloma with cytotoxic agents.
Topics: Acute Disease; Alkylating Agents; Bence Jones Protein; Bone Neoplasms; Carmustine; Cell Count; Cyclo | 1975 |
Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.
Topics: Amino Acid Sequence; Antineoplastic Agents; Bence Jones Protein; Bone Marrow; Bone Marrow Cells; Car | 1975 |
cis-dichlorodiammineplatinum(II) chemotherapy in experimental murine myeloma MOPC 104E.
Topics: Animals; Carmustine; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Dru | 1977 |
[Results of plasmacytoma therapy of ALGB (acute leukemia group B)].
Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; M | 1976 |
Letter: Maintenance therapy in myeloma: risk versus benefit.
Topics: Carmustine; Humans; Leukemia, Myeloid, Acute; Melphalan; Multiple Myeloma; Prednisone | 1975 |
Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line; Cell Survival; Cyclophosphamide; Disease Mode | 1975 |
Combination chemotherapy for myelomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; M | 1992 |
Collateral sensitivity to nitrosoureas in multidrug-resistant cells selected with verapamil.
Topics: Base Sequence; Carmustine; Cell Survival; DNA Repair; Drug Resistance; Gene Expression; Genes; In Vi | 1992 |
Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; | 1992 |
Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Drug Resista | 1992 |
Myeloma cell resistance to melphalan, BCNU and epirubicin determined in vitro with the 3H-thymidine incorporation technique prior to chemotherapy.
Topics: Adult; Bone Marrow; Carmustine; Drug Resistance; Epirubicin; Humans; Immunoglobulins; Melphalan; Mid | 1992 |
Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1991 |
[Preleukemia myelodysplastic syndrome after chemotherapy for multiple myeloma: "a new case"].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Car | 1991 |
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Topics: Blood Transfusion, Autologous; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Dose-Respo | 1990 |
Autopsy-documented cure of multiple myeloma 14 years after M2 chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carmustine; Cyclophosphamide; Female; | 1990 |
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Doxorubicin; Humans; I | 1990 |
[Combination chemotherapy of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclopho | 1990 |
Treatment of multiple myeloma by high dose chemotherapy, total body irradiation and autologous blood stem cell autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Etopos | 1989 |
[Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy].
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1989 |
Combination chemotherapy for multiple myeloma with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Ifosfamide; | 1988 |
[Monoclonal gammapathy of indeterminate origin and myeloma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1988 |
M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine | 1988 |
VBAMDex chemotherapy in advanced multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dexamethasone; Doxorubicin; Follow-Up St | 1988 |
Bone marrow transplantation in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cycl | 1986 |
Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Carmustine; Cyclophosphamide; | 1986 |
[Results with the use of the M-2 protocol in plasmacytoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Eval | 1986 |
Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubi | 1986 |
Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Drug Admi | 1985 |
[Treatment of multiple myeloma in stages II and III with melphalan, prednisone, cyclophosphamide, vincristine and BCNU (M-2 protocol)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Humans; Male; | 1985 |
Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Carmustine; Cyclop | 1985 |
[High-doses BCNU in diseases of the central nervous system caused by myeloma].
Topics: Carmustine; Humans; Meningitis; Multiple Myeloma; Spinal Cord Compression | 1985 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU.
Topics: Adult; Aged; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Melphala | 1974 |
Influence of age of host on the chemotherapy of murine myeloma LCP-1.
Topics: Age Factors; Aging; Alkylating Agents; Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; | 1974 |
Proceedings: Treatment of multiple myeloma by a quadruple chemotherapy regime.
Topics: Carmustine; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Humans; Melphalan; Multiple | 1974 |